Baker Bros. Advisors’s Neurogene NGNE Stock Holding History

Baker Bros. Advisors’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$20M	Hold	991,691	–	–	0.11%	52
2025 Q4	$20.4M	Hold	991,691	–	–	0.12%	53
2025 Q3	$17.2M	Hold	991,691	–	–	0.12%	48
2025 Q2	$14.8M	Sell	991,691 -494,509	-33%	-$7.76M	0.14%	46
2025 Q1	$17.4M	Buy	1,486,200 +811,750	+120%	+$14.1M	0.19%	37
2024 Q4	$15.4M	Buy	674,450 +218,435	+48%	+$8.13M	0.16%	45
2024 Q3	$19.1M	Hold	456,015	–	–	0.2%	43
2024 Q2	$16.6M	Hold	456,015	–	–	0.21%	42
2024 Q1	$23.2M	Buy	456,015 +2,499	+0.6%	+$83.5K	0.29%	38
2023 Q4	$8.79M	Buy	453,516 +148,162	+49%	+$2.12M	0.1%	50
2023 Q3	$4.82M	Buy	305,354 +114,267	+60%	+$1.69M	0.03%	69
2023 Q2	$3.17M	Hold	191,087	–	–	0.02%	85
2023 Q1	$2.68M	Hold	191,087	–	–	0.01%	84
2022 Q4	$1.95M	Hold	191,087	–	–	0.01%	99
2022 Q3	$2.45M	Hold	191,087	–	–	0.02%	98
2022 Q2	$3.94M	Hold	191,087	–	–	0.02%	84
2022 Q1	$7.18M	Hold	191,087	–	–	0.04%	76
2021 Q4	$18.4M	Hold	191,087	–	–	0.09%	60
2021 Q3	$27.6M	Hold	191,087	–	–	0.12%	53
2021 Q2	$35.3M	Hold	191,087	–	–	0.15%	48
2021 Q1	$47M	Hold	191,087	–	–	0.2%	41
2020 Q4	$53.9M	Hold	191,087	–	–	0.2%	32
2020 Q3	$45.9M	Buy	191,087 +21,200	+12%	+$5.14M	0.18%	35
2020 Q2	$56.4M	Hold	169,887	–	–	0.25%	32
2020 Q1	$38.7M	Hold	169,887	–	–	0.24%	32
2019 Q4	$41.9M	Sell	169,887 -395,397	-70%	-$39.4M	0.22%	32
2019 Q3	$32.2M	Buy	565,284 +18,576	+3%	+$1.13M	0.22%	35
2019 Q2	$25.8M	Hold	546,708	–	–	0.18%	38
2019 Q1	$29.5M	Hold	546,708	–	–	0.19%	34
2018 Q4	$23.6M	Hold	546,708	–	–	0.19%	32
2018 Q3	$32M	Hold	546,708	–	–	0.21%	32
2018 Q2	$29M	Hold	546,708	–	–	0.22%	35
2018 Q1	$154M	Hold	546,708	–	–	1.3%	9
2017 Q4	$129M	Hold	546,708	–	–	1.11%	9
2017 Q3	$155M	Hold	546,708	–	–	1.26%	9
2017 Q2	$154M	Hold	546,708	–	–	1.35%	9
2017 Q1	$182M	Buy	546,708 +19,903	+4%	+$6.99M	1.49%	8
2016 Q4	$174M	Hold	526,805	–	–	1.71%	10
2016 Q3	$141M	Buy	526,805 +139,181	+36%	+$28.1M	1.28%	11
2016 Q2	$51.3M	Hold	387,624	–	–	0.54%	20
2016 Q1	$68.4M	Buy	387,624 +50,257	+15%	+$9.77M	0.72%	21
2015 Q4	$84.2M	Hold	337,367	–	–	0.7%	22
2015 Q3	$94.9M	Buy	337,367 +277,499	+464%	+$63.9M	0.88%	17
2015 Q2	$8.31M	Buy	59,868 +485	+0.8%	+$73.8K	0.07%	67
2015 Q1	$9.76M	Sell	59,383 -1,135	-2%	-$231K	0.08%	57
2014 Q4	$9.08M	Sell	60,518 -75	-0.1%	-$10.7K	0.09%	51
2014 Q3	$8.07M	Hold	60,593	–	–	0.1%	49
2014 Q2	$11.4M	Hold	60,593	–	–	0.14%	45
2014 Q1	$15.4M	Buy	+60,593	New	+$15.6M	0.2%	41

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Baker Bros. Advisors's NGNE Position: Q1 2026 in Review

Baker Bros. Advisors held its Neurogene (NGNE) position steady in Q1 2026 at 991,691 shares worth $20M. The position accounts for 0.11% of the portfolio, ranked #52.

Baker Bros. Advisors first reported a position in NGNE in Q1 2014 and has held it in 49 quarters since. The position peaked at $182M in Q1 2017. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

Baker Bros. Advisors held 991,691 shares of Neurogene worth $20M as of Q1 2026.
Baker Bros. Advisors left its Neurogene share count unchanged in Q1 2026.
Neurogene made up 0.11% of Baker Bros. Advisors's portfolio in Q1 2026, its #52 holding.
Baker Bros. Advisors first reported a position in Neurogene in Q1 2014 and has held it in 49 quarters since.
Baker Bros. Advisors's Neurogene position peaked at $182M in Q1 2017.
96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.